Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

Of course, some of the rally’s nothing more than the left-behind stocks playing catch up. The drug stocks had a rare day in ...

Bristol-Myers Squibb announced promising progress on its Phase 2 Alzheimer’s clinical trial of BMS-986446, an experimental ...

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Bristol-Myers Squibb terminated a real-world, non-interventional study on Ozanimod, targeting moderate-to-severe ulcerative ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...